Simplified Onboarding in Adults With Type 2 Diabetes
← catalyst calendarSponsored by Insulet Corporation (industry) · PODD — their whole pipeline →.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
56actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-18 | actual | When the study began enrolling |
| Primary completion | 2026-01-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-06 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes Mellitus
Interventions
- Device: Active Comparator: Omnipod M System with lower starting dose
- Device: Active Comparator: Omnipod M System with higher starting dose
Primary outcomes
what the primary-completion date above is the date OFPercent of time >180 mg/dL
measured Comparing baseline to days 7, 14, 21, and 28 and end of continuation phase in the randomized trial.
Percent of time <70 mg/dL
measured Comparing baseline to days 7, 14, 21, and 28 and end of continuation phase in the randomized trial.
Permalink · PODD's whole pipeline · Catalyst calendar · Every registered study · What changed